Targeting the complex I and III of mitochondrial electron transport chain as a potentially viable option in liver cancer management

Qin Yang, Ling Wang, Jiaye Liu, Wanlu Cao, Qiuwei Pan, Meng Li*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)
1 Downloads (Pure)

Abstract

Liver cancer is one of the most common and lethal types of oncological disease in the world, with limited treatment options. New treatment modalities are desperately needed, but their development is hampered by a lack of insight into the underlying molecular mechanisms of disease. It is clear that metabolic reprogramming in mitochondrial function is intimately linked to the liver cancer process, prompting the possibility to explore mitochondrial biochemistry as a potential therapeutic target. Here we report that depletion of mitochondrial DNA, pharmacologic inhibition of mitochondrial electron transport chain (mETC) complex I/complex III, or genetic of mETC complex I restricts cancer cell growth and clonogenicity in various preclinical models of liver cancer, including cell lines, mouse liver organoids, and murine xenografts. The restriction is linked to the production of reactive oxygen species, apoptosis induction and reduced ATP generation. As a result, our findings suggest that the mETC compartment of mitochondria could be a potential therapeutic target in liver cancer.

Original languageEnglish
Article number293
JournalCell Death Discovery
Volume7
Issue number1
Early online date14 Oct 2021
DOIs
Publication statusPublished - Dec 2021

Fingerprint

Dive into the research topics of 'Targeting the complex I and III of mitochondrial electron transport chain as a potentially viable option in liver cancer management'. Together they form a unique fingerprint.

Cite this